ceftriaxone
Ceftriaxone (Ceftriaxone Sodium) is a cephalosporin antibacterial used to treat Acinetobacter Infections, Infectious Bone Diseases, Chancroid, Clostridium Infections.
Ceftriaxone Sodium · by Qilu Antibiotics
Generic of Ceftriaxone and Dextrose in Duplex Container
Key facts
- Active ingredient
- Ceftriaxone Sodium
- Drug class
- Cephalosporin Antibacterial
- Form
- Injectable, Solution
- Strength
- Ceftriaxone Sodium EQ 1GM BASE/VIAL · Ceftriaxone Sodium EQ 250MG BASE/VIAL · Ceftriaxone Sodium EQ 2GM BASE/VIAL · Ceftriaxone Sodium EQ 500MG BASE/VIAL
- Type
- Prescription (Rx)
- Brand or generic
- Generic
- Manufacturer
- Qilu Antibiotics
- What the pharmacy pays
- ~$42.96 for 30 — not your price
- FDA application
- ANDA203702
What is Ceftriaxone?
From the FDA label:Ceftriaxone for injection, USP is a sterile, semisynthetic, broad-spectrum cephalosporin antibiotic for intravenous or intramuscular administration. Ceftriaxone sodium is (6 R ,7 R )-7-[2-(2-Amino-4-thiazolyl)glyoxylamido]-8-oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo- as -triazin-3-yl)thio]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7 2 -( Z )-( O -methyloxime), disodium salt, sesquaterhydrate. The chemical formula of ceftriaxone sodium is C 18 H 16 N 8 Na 2 O 7 S 3 •3.5H 2 O. It has a calculated molecular weight of 661.59 and the following structural formula: Ceftriaxone for injection, USP is a white to yellowish-orange crystalline powder which is readily soluble in water, sparingly soluble in methanol and very slightly soluble in ethanol. The pH of a 1% aqueous solution is approximately 6.7. The color of Ceftriaxone for injection, USP solutions ranges from light yellow to amber, depending on the length of storage, concentration and diluent used. Each vial contains ceftriaxone sodium equivalent to 250 mg, 500 mg, 1 g or 2 g of ceftriaxone activity. Ceftriaxone for injection, USP contains approximately 83 mg (3.6 mEq) of sodium per gram of ceftriaxone activity. Chemical Structure
How to use
Ceftriaxone is sold in more than one form (Injectable and Solution), and each is dosed differently. The instructions below come from the FDA label for application ANDA203702 — follow the label that came with the product you were actually prescribed.
Ceftriaxone for injection may be administered intravenously or intramuscularly. Do not use diluents containing calcium, such as Ringer’s solution or Hartmann’s solution, to reconstitute Ceftriaxone for injection vials or to further dilute a reconstituted vial for IV administration because a precipitate can form. Precipitation of ceftriaxone-calcium can also occur when Ceftriaxone for injection is mixed with calcium-containing solutions in the same IV administration line. Ceftriaxone for injection must not be administered simultaneously with calcium-containing IV solutions, including continuous calcium-containing infusions such as parenteral nutrition via a Y-site. However, in patients other than neonates, Ceftriaxone for injection and calcium-containing solutions may be administered sequentially of one another if the infusion lines are thoroughly flushed between infusions with a compatible fluid (see WARNINGS ). There have been no reports of an interaction between ceftriaxone and oral calcium-containing products or interaction between intramuscular ceftriaxone and calcium-containing products (IV or oral). NEONATES: Hyperbilirubinemic neonates, especially prematures, should not be treated with Ceftriaxone for injection. Ceftriaxone for injection is contraindicated in premature neonates (see CONTRAINDICATIONS ). Ceftriaxone for injection is contraindicated in neonates (≤ 28…
Side effects
Ceftriaxone for injection is generally well tolerated. In clinical trials, the following adverse reactions, which were considered to be related to Ceftriaxone for injection therapy or of uncertain etiology, were observed: LOCAL REACTIONS —pain, induration and tenderness was 1% overall. Phlebitis was reported in <1% after IV administration. The incidence of warmth, tightness or induration was 17% (3/17) after IM administration of 350 mg/mL and 5% (1/20) after IM administration of 250 mg/mL. GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS— injection site pain (0.6%). HYPERSENSITIVITY —rash (1.7%). Less frequently reported (<1%) were pruritus, fever or chills. INFECTIONS AND INFESTATIONS —genital fungal infection (0.1%). HEMATOLOGIC —eosinophilia (6%), thrombocytosis (5.1%) and leukopenia (2.1%). Less frequently reported (<1%) were anemia, hemolytic anemia, neutropenia, lymphopenia, thrombocytopenia and prolongation of the prothrombin time. BLOOD AND LYMPHATIC DISORDERS— granulocytopenia (0.9%), coagulopathy (0.4%). GASTROINTESTINAL —diarrhea/loose stools (2.7%). Less frequently reported (<1%) were nausea or vomiting, and dysgeusia. The onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment (see WARNINGS ). HEPATIC —elevations of aspartate aminotransferase (AST) (3.1%) or alanine aminotransferase (ALT) (3.3%). Less frequently reported…
Warnings
Important safety information
Hypersensitivity Reactions Before therapy with Ceftriaxone for injection is instituted, careful inquiry should be made to determine whether the patient has had previous hypersensitivity reactions to cephalosporins, penicillins and other beta-lactam agents or other drugs. This product should be given cautiously to penicillin and other beta-lactam agent-sensitive patients. Antibacterial drugs should be administered with caution to any patient who has demonstrated some form of allergy, particularly to drugs. Serious acute hypersensitivity reactions may require the use of subcutaneous epinephrine and other emergency measures. As with all beta-lactam antibacterial agents, serious and occasionally fatal hypersensitivity reactions (i.e., anaphylaxis) have been reported. In case of severe hypersensitivity reactions, treatment with ceftriaxone must be discontinued immediately and adequate emergency measures must be initiated. Interaction with Calcium-Containing Products Do not use diluents containing calcium, such as Ringer’s solution or Hartmann’s solution, to reconstitute Ceftriaxone for injection vials or to further dilute a reconstituted vial for IV administration because a precipitate can form. Precipitation of ceftriaxone-calcium can also occur when Ceftriaxone for injection is mixed with calcium-containing solutions in the same IV administration line. Ceftriaxone for injection must not be administered simultaneously with calcium-containing IV solutions, including continuous calcium-containing infusions such as parenteral nutrition via a Y-site. However, in patients other than neonates, Ceftriaxone for injection and calcium-containing solutions may be administered sequentially of one another if the infusion lines are thoroughly flushed between infusions with a compatible fluid. In vitro studies using adult and neonatal plasma from umbilical cord blood demonstrated that neonates have an increased risk of precipitation of ceftriaxone-calcium (see CLINICAL PHARMACOLOGY , CONTRAINDICATIONS and DOSAGE AND ADMINISTRATION ). Clostridium difficile -Associated Diarrhea Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Ceftriaxone for injection, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile . C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile , and surgical evaluation should be instituted as clinically indicated. Hemolytic Anemia An immune mediated hemolytic anemia has been observed in patients receiving cephalosporin class antibacterials including Ceftriaxone for injection. Severe cases of hemolytic anemia, including fatalities, have been reported during treatment in both adults and children. If a patient develops anemia while on ceftriaxone, the diagnosis of a cephalosporin associated anemia should be considered and ceftriaxone stopped until the etiology is determined.
Who should not take Ceftriaxone
Hypersensitivity Ceftriaxone for injection is contraindicated in patients with known hypersensitivity to ceftriaxone, any of its excipients or to any other cephalosporin. Patients with previous hypersensitivity reactions to penicillin and other beta lactam antibacterial agents may be at greater risk of hypersensitivity to ceftriaxone (see WARNINGS – Hypersensitivity ). Neonates Premature neonates : Ceftriaxone for injection is contraindicated in premature neonates up to a postmenstrual age of 41 weeks (gestational age + chronological age). Hyperbilirubinemic neonates : Hyperbilirubinemic neonates should not be treated with Ceftriaxone for injection. Ceftriaxone can displace bilirubin from its binding to serum albumin, leading to a risk of bilirubin encephalopathy in these patients. Neonates Requiring Calcium Containing IV Solutions Ceftriaxone for injection is contraindicated in neonates (≤ 28 days) if they require (or are expected to require) treatment with calcium-containing IV solutions, including continuous calcium-containing infusions such as parenteral nutrition because of the risk of precipitation of ceftriaxone-calcium (see CLINICAL PHARMACOLOGY , WARNINGS and DOSAGE AND ADMINISTRATION ). Cases of fatal outcomes in which a crystalline material was observed in the lungs and kidneys at autopsy have been reported in neonates receiving Ceftriaxone for injection and calcium-containing fluids. In some of these cases, the same intravenous infusion line was used for both Ceftriaxone for injection and calcium-containing fluids and in some a precipitate was observed in the intravenous infusion line. There have been no similar reports in patients other than neonates. Lidocaine Intravenous administration of ceftriaxone solutions containing lidocaine is contraindicated. When lidocaine solution is used as a solvent with ceftriaxone for intramuscular injection, exclude all contraindications to lidocaine. Refer to the prescribing information of lidocaine.
Overdose — what happens if you take too much
In the case of overdosage, drug concentration would not be reduced by hemodialysis or peritoneal dialysis. There is no specific antidote. Treatment of overdosage should be symptomatic.
U.S. Poison Control: call or text 1-800-222-1222 (free, 24/7). In an emergency call 911. From the FDA label; not medical advice.
Drug class
How this class works, per Cephalosporins - StatPearls - NCBI Bookshelf.
May treat (source: NIH RxClass)
- acinetobacter infections
- infectious bone diseases
- chancroid
- clostridium infections
- enteritis
- epididymitis
See how Ceftriaxone ranks — best-rated cephalosporin antibacterial for:
Dosage forms
Injectable and Solution
The forms currently marketed in the U.S., per the FDA National Drug Code Directory.
Ways to save
Ask for the generic
Same active ingredient, far cheaper. Is there a generic? →
Request a 90-day supply
Bulk fills usually lower the per-dose price vs monthly refills.
Use copay cards
Manufacturer copay cards & patient-assistance programs — especially for brand drugs.
Compare alternatives
A same-class option may cost less. See alternatives →
Frequently asked questions
- What does Ceftriaxone treat?
- Ceftriaxone (Ceftriaxone Sodium) may be used to treat acinetobacter infections, infectious bone diseases, chancroid, clostridium infections, enteritis, epididymitis, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.
- How does Ceftriaxone work?
- Ceftriaxone is a cephalosporin antibacterial. Cephalosporins kill bacteria by blocking the proteins they use to build their cell walls. Without an intact wall, the bacterium cannot hold its shape and dies, which clears the infection.
- How much does Ceftriaxone cost?
- Nobody can tell you what you will pay — your price is set by your insurer's formulary, your deductible and the pharmacy's markup, and none of those are published. What IS published is what the pharmacy paid to acquire it: about $42.96 for 30, per the CMS NADAC survey. Treat that as the floor, not the quote — ask the pharmacist for the cash price as well as your copay, because for cheap generics the cash price often wins. Pharmacies pay less for a same-class option, Cefazolin and Dextrose — about $29.65 on the same basis.
- Is there a coupon or discount for Ceftriaxone?
- pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Ceftriaxone. To pay less, Ceftriaxone is already a generic — usually the lowest-cost version — so the main levers are comparing cash prices between pharmacies and using a pharmacy discount-card service. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
- Who makes Ceftriaxone?
- Ceftriaxone is marketed by Qilu Antibiotics. You can see Qilu Antibiotics's full profile, rating, and other products on pharmaranks.
- Is Ceftriaxone a brand-name or generic drug?
- Ceftriaxone is a generic medication; its active ingredient is Ceftriaxone Sodium. Generics contain the same active ingredient as the brand-name original and are usually lower cost.
- Is Ceftriaxone available over the counter?
- No. Ceftriaxone is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
- What forms does Ceftriaxone come in?
- Ceftriaxone is currently marketed as injectable and solution, per the FDA's National Drug Code Directory.
- What class of drug is Ceftriaxone?
- Ceftriaxone is classified as cephalosporin antibacterial, per the FDA's Established Pharmacologic Class.
- Is Ceftriaxone FDA-registered?
- Ceftriaxone is on record with the U.S. FDA under application number ANDA203702. You can verify this on its official FDA label.
- Is Ceftriaxone safe?
- There's no single safe-or-not verdict, and we don't yet have a composite recall-safety score for Ceftriaxone. Review its FDA-label side effects and warnings below, and always consult a licensed professional.
- What are the side effects of Ceftriaxone?
- Ceftriaxone's side effects are taken directly from its FDA label. From the label: Ceftriaxone for injection is generally well tolerated. In clinical trials, the following adverse reactions, which were considered to be related to Ceftriaxone for injection therapy or of uncertain etiology, were observed: LOCAL REACTIONS —pain, induration and tenderness was 1% overall.… Both common and serious reactions are documented in full on this page. This is general reference from the FDA, not medical advice — always consult a professional.
Clinical content sourced from the FDA label via openFDA (U.S. FDA). View the FDA label on DailyMed → Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.
Reviews
No reviews yet. Be the first to write one.
People also viewed
cefixime
Cefixime
cefotan
Cefotetan Disodium
fetroja
Cefiderocol Sulfate Tosylate
cefazolin and dextrose
Cefazolin Sodium
cefazolin sodium
Cefazolin Sodium
cefepime hydrochloride
Cefepime Hydrochloride
Compare Ceftriaxone head-to-head
More cephalosporin antibacterial drugs
Browse medications A–Z
Research products from A to Z, compare independent ratings, and find alternatives.
ceftriaxone
New